We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+48.28%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$392M
AUM Growth
+$42.8M
Cap. Flow
-$39.5M
Cap. Flow %
-10.09%
Top 10 Hldgs %
70.95%
Holding
53
New
14
Increased
7
Reduced
6
Closed
18

Top Buys

Rank Stock Value
1
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$20.9M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$14.5M
3
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$12.9M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$7.48M
5
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$5.91M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$25M
2
BLUE
bluebird bio
BLUE
+$21.6M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$21.3M
4
XNCR icon
Xencor
XNCR
+$8.55M
5
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$7.4M

Sector Composition

Rank Sector Weight
1 Healthcare 77.25%
2 Technology 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TTPH
26
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.73M 0.44%
22,619
-92,357
-80% -$7.4M
ATXS
27
DELISTED
Astria Therapeutics
ATXS
$1.54M 0.39%
+4,167
New +$1.1M
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.5M 0.38%
+227,657
New +$1.21M
MCRB icon
29
Seres Therapeutics
MCRB
$46.8M
$1.48M 0.38%
+6,000
New +$2.11M
MCRB icon
30
PUT
Seres Therapeutics
MCRB
$46.8M
$1.48M 0.38%
6,000
– –
RCKT icon
31
Rocket Pharmaceuticals
RCKT
$340M
$892K 0.23%
+23,519
New +$740K
NVAX icon
32
CALL
Novavax
NVAX
$1.2B
$851K 0.22%
+20,460
New +$2.64M
STRM
33
DELISTED
Streamline Health Solutions
STRM
$279K 0.07%
10,107
– –
ARDX icon
34
Ardelyx
ARDX
$1.22B
$194K 0.05%
15,000
+11,556
+336% +$121K
ISEE
35
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$157K 0.04%
+3,400
New +$192K
ADVM
36
DELISTED
Adverum Biotechnologies
ADVM
– –
-55,012
Closed -$1.74M
AMRN
37
Amarin Corp
AMRN
$299M
– –
-100
Closed -$4K
ARCT icon
38
Arcturus Therapeutics
ARCT
$164M
– –
-202,082
Closed -$6.35M
ASND icon
39
Ascendis Pharma A/S
ASND
$16B
– –
-76,511
Closed -$1.01M
AUPH icon
40
Aurinia Pharmaceuticals
AUPH
$1.91B
– –
-2,457,144
Closed -$7.19M
BLUE
41
DELISTED
bluebird bio
BLUE
– –
-38,600
Closed -$21.6M
EXEL icon
42
Exelixis
EXEL
$13.3B
– –
-3,200,000
Closed -$25M
LSTA icon
43
Lisata Therapeutics
LSTA
$9.02M
– –
-10,168
Closed -$900K
RIGL icon
44
Rigel Pharmaceuticals
RIGL
$681M
– –
-5,000
Closed -$112K
SRPT icon
45
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-238,900
Closed -$4.56M
VCEL icon
46
Vericel Corp
VCEL
$2.35B
– –
-253,502
Closed -$570K
XNCR icon
47
Xencor
XNCR
$1.5B
– –
-450,000
Closed -$8.55M
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-100,000
Closed -$3.88M
RVNC
49
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-21,665
Closed -$295K
EGRX
50
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-548,290
Closed -$21.3M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2016 Portfolio in Review

As of Q3 2016, Great Point Partners held 53 positions worth $392M, up 12% from $349M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Great Point Partners withdrew a net $39.5M in Q3 2016, closing 18 positions and reducing 6 holdings. Its most notable exit was Exelixis, an estimated $25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 74% a quarter earlier, followed by Technology.

Against the trend, Great Point Partners opened a new position in AveXis, Inc. Common Stock worth $15.7M.

  • Great Point Partners's largest Q3 2016 buy was AveXis, Inc. Common Stock: 381,095 shares worth $15.7M.
  • Great Point Partners added most to Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2016, an estimated $20.9M increase.
  • Great Point Partners's biggest Q3 2016 reduction was Tetraphase Pharmaceuticals, Inc., cutting an estimated $7.4M.
  • Great Point Partners fully exited Exelixis in Q3 2016, selling an estimated $25M.
  • Great Point Partners's ten largest holdings make up 71% of its $392M portfolio in Q3 2016.
  • Great Point Partners opened 14 new positions and closed 18 in Q3 2016.
  • Great Point Partners's portfolio value rose 12% quarter-over-quarter to $392M.

Based on Great Point Partners's 13F filing for Q3 2016, filed 14 Nov 2016.